STOCK TITAN

XORTX Therapeutics Inc. - XRTX STOCK NEWS

Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.

XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.

The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.

One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.

Rhea-AI Summary

XORTX Therapeutics has submitted a Type D meeting request to the FDA for its clinical program concerning XRX-OXY-301, aiming to expedite the approval process for XORLOTM, its innovative treatment for autosomal dominant polycystic kidney disease (ADPKD). A virtual meeting is set for May 1, 2023. The revised protocol aims to gather data necessary for accelerated approval of the drug based on total kidney volume metrics. The trial will target patients with stages 2-4 ADPKD and high uric acid levels and is expected to commence in the latter half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics reported significant progress in 2022, setting a robust foundation for its 2023 goals focused on advancing technology and clinical trials for treating progressive kidney disease. Key milestones included the completion of the XRX-OXY-101 clinical study and successful regulatory submissions to the FDA and Health Canada for the XRx-008 program targeting autosomal dominant polycystic kidney disease (ADPKD). In 2023, XORTX aims to initiate a Phase 3 trial for XORLO™ to gain 'Accelerated Approval' and secure Orphan Drug Designation. Financially, the company completed a $5 million public offering. XORTX seeks strategic partnerships to advance its ambitious agenda.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics submitted an Orphan Drug Designation request to the FDA for its XRx-008 program aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This designation, intended for rare diseases affecting fewer than 200,000 individuals in the US, offers several advantages such as seven years of post-approval exclusivity and tax credits on clinical testing expenses. The XRx-008 program utilizes XORLO, a proprietary formulation of oxypurinol, which showed positive results in animal models, potentially slowing the decline of kidney function in ADPKD patients. The company will provide updates on the ODD application as they become available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.47%
Tags
none
Rhea-AI Summary

XORTX Therapeutics announced positive topline results from the XRX-OXY-101 trial, which evaluates the pharmacokinetics of XORLO™. This oral formulation of oxypurinol showed significant improvements in bioavailability and safety across 88 subjects. Key findings include:

  • Over 100% increase in bioavailability compared to non-formulated oxypurinol.
  • 40% higher exposure when taken with food.
  • Consistent target therapeutic values achieved in multiple dosing.
  • Confirmed innovations from newly granted US and EU patents.

This data will inform dosing in the upcoming Phase 3 trial for patients with autosomal dominant polycystic kidney disease (ADPKD).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
-
Rhea-AI Summary

XORTX Therapeutics (NASDAQ: XRTX), a late-stage pharmaceutical company, has submitted a Patent Cooperation Treaty (PCT) application for a patent titled “Compositions and Methods for Diagnosis, Treatment and Prevention of Kidney Disease”. This application stems from findings indicating a diagnostic and therapeutic opportunity related to polycystic kidney disease (PKD). The patent proposes methods to identify patients at risk of accelerated kidney disease progression through aberrant purine metabolism and hyperuricemia, aiming to personalize treatment approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics has completed dosing for its XRX-OXY-101 pharmacokinetics bridging study, part of the development for its proprietary oral oxypurinol formulation, XORLOTM. This study aims to assess the pharmacokinetics in healthy individuals and informs the upcoming phase 3 trial for treating autosomal dominant polycystic kidney disease (ADPKD). The study comprises four parts, with topline results from parts 3 and 4 expected soon. Company CEO Allen Davidoff highlighted that results will guide dosing and support FDA submissions. Consolidated results are anticipated in January 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.75%
Tags
Rhea-AI Summary

XORTX Therapeutics has announced promising results from an independent study indicating that its proprietary formulation, XORLO™, effectively inhibits kidney expansion in a mouse model of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Conducted at the University of Colorado, the study supports prior data presented at the American Society of Nephrology meeting. Key findings include a significant correlation between increased uric acid levels and kidney volume, with XORLO™ mitigating these harmful effects. CEO Allen Davidoff highlighted the relevance of these findings for future clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics (NASDAQ: XRTX) has announced the successful enrollment of participants in the XRX-OXY-101 Bridging Pharmacokinetics Study, aimed at optimizing the formulation and dosage of oxypurinol for treating ADPKD. The trial's completion and topline results are expected soon, which will inform the dosing for the upcoming Phase 3 XRX-OXY-301 trial. Additionally, the company granted 70,000 stock options to certain officers at an exercise price of $1.38 for five years, indicating ongoing engagement with its leadership team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics Inc. announced it has received a notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its shares traded below $1.00 for 30 consecutive business days. Despite this, the company's listing on Nasdaq remains unaffected at this time. XORTX has 180 days to regain compliance. The firm is focused on developing therapies for progressive kidney diseases and has advanced clinical programs including XRx-008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
Rhea-AI Summary

XORTX Therapeutics has appointed Dr. Stacy Evans as Chief Business Officer to spearhead the search for a global partner for the Phase 3 development of its XRx-008 program, targeting autosomal dominant polycystic kidney disease (ADPKD). With nearly 25 years of experience, including 12 years at Pfizer, Dr. Evans will enhance the company's business development outreach. Additionally, Russo Partners will manage public relations for XORTX, further strengthening its market position. XRX-008 is poised for clinical trials in 2023, with recent patent grants aiding the program's progression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.99%
Tags
management

FAQ

What is the current stock price of XORTX Therapeutics (XRTX)?

The current stock price of XORTX Therapeutics (XRTX) is $1.265 as of November 21, 2024.

What is the market cap of XORTX Therapeutics (XRTX)?

The market cap of XORTX Therapeutics (XRTX) is approximately 4.1M.

What is XORTX Therapeutics Inc.?

XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies to treat progressive kidney diseases worldwide.

What are the main diseases XORTX targets?

XORTX targets progressive kidney diseases such as diabetic nephropathy, polycystic kidney disease, and complications from diabetes and cardiovascular diseases.

Where is XORTX Therapeutics headquartered?

XORTX Therapeutics Inc. is headquartered in Calgary, Canada.

What is TMX-049?

TMX-049 is a xanthine oxidoreductase inhibitor being developed by XORTX in collaboration with Teijin Pharma Limited.

Who are XORTX's strategic partners?

XORTX has strategic partnerships with Teijin Pharma Limited and the Icahn School of Medicine.

What stage is XORTX Therapeutics in?

XORTX Therapeutics Inc. is a clinical-stage biotechnology company.

What health issues does XORTX aim to address?

XORTX aims to address health issues related to aberrant purine and uric acid metabolism, such as diabetic nephropathy, hypertension, insulin resistance, and metabolic syndrome.

What is the focus of XORTX's pipeline?

The focus of XORTX's pipeline includes developing therapies to slow or reverse chronic kidney diseases and addressing acute kidney injury due to respiratory virus infections.

What are xanthine oxidase inhibitors?

Xanthine oxidase inhibitors are a class of drugs that reduce uric acid production and are being developed by XORTX to manage conditions like diabetic nephropathy.

How does XORTX contribute to COVID-19 research?

XORTX collaborates with the Icahn School of Medicine to study acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc.

Nasdaq:XRTX

XRTX Rankings

XRTX Stock Data

4.06M
3.13M
3.02%
6.03%
0.07%
Biotechnology
Healthcare
Link
United States of America
Alberta Beach